Genprex

Category: Press Releases

Genprex to Participate in CEO Roadshow Webinar Series

Webinar series will feature a weekly company overview highlighting the Genprex’s gene therapy pipeline in cancer and diabetes

Read More

Genprex to Receive Inaugural “License of the Year” Award from University of Pittsburgh Innovation Institute in Recognition of Advances Made with Gene Therapy Program in Diabetes

Groundbreaking, potentially curative gene therapy shown to transform alpha cells in the pancreas into functional beta-like cells is potentially applicable to both Type 1 and Type 2 diabetes

Read More

Genprex Collaborators Report Positive Preclinical Data for REQORSA™ Immunogene Therapy in Non-Small Cell Lung Cancer at the 2021 AACR Annual Meeting

Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at the 2021 Virtual Cell & Gene Meeting on the Mediterranean

Company overview to highlight novel gene therapies for cancer and diabetes

Read More

Genprex Announces Preclinical Data for TUSC2 Immunogene Therapy in Non-Small Cell Lung Cancer to Be Featured in Two Presentations at the 2021 American Association for Cancer Research Annual Meeting

Two Featured Presentations will Highlight Potential of TUSC2 Immunogene Therapy to Enhance Chemo-Immune Combination Treatments and Overcome Resistance to Osimertinib

Read More

Genprex to Present at the Spring 2021 Oncology Investor Conference on March 29

Investor presentation to highlight novel gene therapies for cancer and diabetes

Read More

Genprex to Participate in Upcoming March Investor Conferences

Investor presentations to highlight novel gene therapies for cancer and diabetes

Read More

Genprex, Inc. Announces $25 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules, Without Warrants

Genprex has entered into securities purchase agreements with two healthcare-dedicated institutional investors for the purchase and sale of 4,000,000 shares of its common stock at a purchase price of $6.25 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Read More

Genprex Announces Formation of Clinical Advisory Board

World reknowned medical and clinical experts to guide Genprex’ novel gene therapy clinical development programs in cancer and diabetes, including its two upcoming clinical trials in lung cancer

Read More

Genprex Recognizes World Cancer Day

Joins Global Movement to Raise Awareness and Reduce the Burden of Cancer Worldwide

Read More